UNASSIGNED: A mixed-methodology IDEAL stage 1 study.
UNASSIGNED: A single tertiary care centre.
UNASSIGNED: Six patients consented and four downloaded and engaged with the mHealth application throughout the 12 weeks of the study.
UNASSIGNED: Over a 12-week period, we collected real-world and ePRO data via Vinehealth. We assessed qualitative feedback from mixed-methodology surveys and semistructured interviews at recruitment and after 2 weeks.
UNASSIGNED: 565 data points were captured including, but not limited to: symptoms, activity, well-being and medication. EORTC QLQ-BN20 and EQ-5D-5L completion rates (54% and 46%) were impacted by technical issues; 100% completion rates were seen when ePROs were received. More brain cancer tumour-specific content was requested. All participants recommended the application and felt it improved care.
UNASSIGNED: Our findings indicate value in an application to holistically support patients living with brain cancer tumours and established the feasibility and safety of further studies to more rigorously assess this.
未经批准:混合方法理想的第一阶段研究。
UNASSIGNED:一个单一的三级护理中心。
未经评估:在研究的12周内,有6名患者同意,4名患者下载并参与了mHealth应用程序。
未经批准:在12周内,我们通过Vinehealth收集了真实世界和EPRO数据。我们在招聘时和2周后评估了混合方法调查和半结构化访谈的定性反馈。
未经评估:捕获了565个数据点,包括:但不限于:症状,活动,健康和药物。EORTCQLQ-BN20和EQ-5D-5L完成率(54%和46%)受到技术问题的影响;收到EPR时,完成率为100%。需要更多的脑癌肿瘤特异性内容。所有参与者都推荐了该应用程序,并认为它改善了护理。
UNASSIGNED:我们的研究结果表明,在整体支持脑癌患者的应用中具有价值,并建立了进一步研究的可行性和安全性,以更严格地评估这一点。